MediciNova, Inc., a biopharmaceutical company listed on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of ...
Phase 1/2 Trial Confirms Safety With Repeated Dosing Supporting Further Development in Early-stage Disease and Combination ...
Key factors driving this growth include the rising prevalence of cancer, continuous advancements in CAR T-cell technologies, a ...
First real-world evidence for a menin inhibitor shows 77% ORR (10/13), 31% (4/13) CR/CRh, 75% (9/12) MRD negativity, and favorable tolerability ...
Discusses ASH Conference Data Updates and Portfolio Progress Including Anemia and Iron Restriction Programs December 7, 2025 ...
Trial Design Finalized in Consultation and Alignment with U.S. Food and Drug Administration Study Designed to Establish a New ...
The relationship between nutrition, metabolism, and brain health is an expanding field crucial to understanding cognitive aging and disease prevention.
Inherited myopathies (IM) constitute a heterogeneous group of genetically based conditions that, regardless of the specific ...
Summary • Biodexa Pharmaceuticals Plc (BDRX) shares surged 41.3% to $7.12 with over 10.7 million shares traded.• The increase ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback